tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

VYNE Stock Latest News

VYNE Therapeutics Reports Q3 2025 Financial Results
Company AnnouncementsVYNE Therapeutics Reports Q3 2025 Financial Results
3d ago
VYNE
VYNE Therapeutics reports Q3 EPS (17c) vs (29c) last year
PremiumThe Fly
VYNE Therapeutics reports Q3 EPS (17c) vs (29c) last year
3d ago
VYNE
VYNE Therapeutics Faces Nasdaq Non-Compliance Notice
PremiumCompany Announcements
VYNE Therapeutics Faces Nasdaq Non-Compliance Notice
2M ago
8K
VYNE
VYNE Therapeutics Reports Q2 2025 Financials and Updates
PremiumCompany Announcements
VYNE Therapeutics Reports Q2 2025 Financials and Updates
3M ago
VYNE
VYNE Therapeutics: Hold Rating Amid Mixed Clinical Outcomes and Financial Sustainability
PremiumRatings
VYNE Therapeutics: Hold Rating Amid Mixed Clinical Outcomes and Financial Sustainability
3M ago
VYNE
VYNE Therapeutics Directors Resign Amid Financial Updates
PremiumCompany AnnouncementsVYNE Therapeutics Directors Resign Amid Financial Updates
3M ago
8K
VYNE
VYNE Therapeutics reports Q2 EPS (13c) vs (22c) last year
Premium
The Fly
VYNE Therapeutics reports Q2 EPS (13c) vs (22c) last year
3M ago
VYNE
VYNE Earnings this Week: How Will it Perform?
Premium
Pre-Earnings
VYNE Earnings this Week: How Will it Perform?
3M ago
VYNE
Watch Out! Analysts Have Recently Downgraded These Stocks
PremiumMarket News
Watch Out! Analysts Have Recently Downgraded These Stocks
3M ago
AMD
NEO
Why Is VYNE Therapeutics Stock (VYNE) Down 70% Today?
PremiumMarket News
Why Is VYNE Therapeutics Stock (VYNE) Down 70% Today?
3M ago
VYNE
VYNE Therapeutics downgraded to Neutral from Buy at BTIG
PremiumThe Fly
VYNE Therapeutics downgraded to Neutral from Buy at BTIG
3M ago
VYNE
VYNE Therapeutics: Buy Rating Supported by Promising VYN202 Prospects Amidst Challenges
PremiumRatings
VYNE Therapeutics: Buy Rating Supported by Promising VYN202 Prospects Amidst Challenges
3M ago
VYNE
Morning News Wrap-Up: Wednesday’s Biggest Stock Market Stories!
PremiumMarket NewsMorning News Wrap-Up: Wednesday’s Biggest Stock Market Stories!
3M ago
MO
QS
VYNE Therapeutics downgraded at H.C. Wainwright after vitiligo trial miss
Premium
The Fly
VYNE Therapeutics downgraded at H.C. Wainwright after vitiligo trial miss
3M ago
VYNE
VYNE Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
Premium
The Fly
VYNE Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
3M ago
VYNE
VYNE Therapeutics Ends Phase 2b Trial for Repibresib
PremiumCompany Announcements
VYNE Therapeutics Ends Phase 2b Trial for Repibresib
3M ago
8K
VYNE
VYNE says Phase 2B trial with repibresib gel did not meet primary endpoint
PremiumThe Fly
VYNE says Phase 2B trial with repibresib gel did not meet primary endpoint
3M ago
VYNE
Promising Developments in VYNE Therapeutics’ Repibresib Gel for Nonsegmental Vitiligo Drive Buy Rating
PremiumRatings
Promising Developments in VYNE Therapeutics’ Repibresib Gel for Nonsegmental Vitiligo Drive Buy Rating
4M ago
VYNE
Promising Potential of VYNE Therapeutics’ Repibresib Gel in Phase IIb Study
PremiumRatings
Promising Potential of VYNE Therapeutics’ Repibresib Gel in Phase IIb Study
4M ago
VYNE
Promising Outlook for VYNE Therapeutics: Buy Rating Backed by Repibresib’s Potential in Vitiligo Treatment
PremiumRatingsPromising Outlook for VYNE Therapeutics: Buy Rating Backed by Repibresib’s Potential in Vitiligo Treatment
4M ago
VYNE
VYNE Therapeutics’ VYN202: Regulatory Milestones and Promising Clinical Data Drive Buy Rating
Premium
Ratings
VYNE Therapeutics’ VYN202: Regulatory Milestones and Promising Clinical Data Drive Buy Rating
4M ago
VYNE
H.C. Wainwright ‘encouraged’ by VYNE Therapeutics VYN202 update
Premium
The Fly
H.C. Wainwright ‘encouraged’ by VYNE Therapeutics VYN202 update
4M ago
VYNE

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >